Patents by Inventor Burcu Caliskan

Burcu Caliskan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating cancer
    Patent number: 11986475
    Abstract: Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
    Type: Grant
    Filed: November 13, 2023
    Date of Patent: May 21, 2024
    Assignees: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Chaemin Lim, Sridhar Vempati, Erden Banoglu, Burcu Caliskan, Ozgur Sahin
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240156813
    Abstract: Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
    Type: Application
    Filed: November 13, 2023
    Publication date: May 16, 2024
    Inventors: Chaemin Lim, Sridhar Vempati, Erden Banoglu, Burcu Caliskan, Ozgur Sahin
  • Highly potent TACC3 inhibitor as a novel anticancer drug candidate
    Patent number: 11622966
    Abstract: The present invention relates to a new inhibitor chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264) targeting TACC3 protein with high potency as a mitotic blocker for the treatment of breast and potentially other cancers.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 11, 2023
    Assignees: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Erden Banoglu, Burcu Caliskan, Ozgur Sahin, Deniz Lengerli, Ozge Akbulut
  • ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS
    Publication number: 20230027854
    Abstract: In one aspect, the present disclosure relates to compounds and compositions capable of inhibiting TACC3. In another aspect, the present disclosure relates to methods of treating TACC3 mediated diseases and disorders.
    Type: Application
    Filed: November 13, 2020
    Publication date: January 26, 2023
    Inventors: Erden Banoglu, Burcu Caliskan, Ozgur Sahin, Deniz Lengerli, Ozge Akbulut, Chaemin Lim, Emmanuel Cruz, Sridhar Vempati, Kubra Ibis
  • HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE
    Publication number: 20210220369
    Abstract: The present disclosure relates to 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine and methods of use thereof.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 22, 2021
    Applicants: A2A Pharmaceuticals, Inc., OncoCube Therapeutics LLC
    Inventors: Erden Banoglu, Burcu Caliskan, Ozgur Sahin, Deniz Lengerli, Ozge Akbulut